Shares of Acadia Pharmaceuticals ACAD lost 9.9% on Wednesday after the company announced a disappointing update from a late-stage study of its investigational candidate, intranasal carbetocin (ACP-101 ...

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United ...

Acadia Pharmaceuticals ACAD announced that it has signed an exclusive worldwide license agreement with Saniona, a Denmark-based clinical-stage biopharmaceutical company, to develop and commercialize ...

Acadia Pharmaceuticals (ACAD) shares ended the last trading session 6.1% higher at $14.96. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) stock jumped 26.6% to $22.29 on Friday afternoon following a favorable court ruling. What To Know: The U.S. District Court for the District of Delaware upheld ...

In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $16.68, changing hands as high as $16.82 per share. Acadia Pharmaceuticals Inc ...

Multiple analysts have issued price targets for $ACAD recently. We have seen 16 analysts offer price targets for $ACAD in the last 6 months, with a median target of ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...